NCIt definition : A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific
membrane protein CD-19 with potential immunostimulating and antineoplastic activities.
Inebilizumab binds to CD19, which may result in a cytotoxic T-lymphocyte (CTL) response
and antibody-dependent cellular cytotoxicity (ADCC) to CD19-expressing B-cells. The
Fc portion of inebilizumab does not contain a fucose sugar moiety, which may contribute
to its enhanced ADCC activity. CD19 is a membrane antigen that is widely expressed
during B-cell development, from pro-B-cell to early plasma cell stages.;
UNII : 74T7185BMM;
CAS number : 1299440-37-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1299440-37-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;